Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates

Nucleic Acids Research

Volumn 38, Issue 20, 2010, Pages 7100-7111

  Straarup, Ellen Marie ^a   Fisker, Niels ^a   Hedtjärn, Maj ^a   Lindholm, Marie W ^a   Rosenbohm, Christoph ^a   Aarup, Vibeke ^a   Hansen, Henrik Frydenlund ^a   Ørum, Henrik ^a   Hansen, Jens B Rode ^a   Koch, Troels ^a  

^a Santaris Pharma AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; CHOLESTEROL; LOCKED NUCLEIC ACID; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIMATE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; APOLIPOPROTEINS B; AUTORADIOGRAPHY; BASE PAIR MISMATCH; CELL LINE, TUMOR; CHOLESTEROL; FEMALE; HUMANS; MACACA FASCICULARIS; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER;

MUS; PRIMATES;

EID: 78649877710     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkq457     Document Type: Article

References (39)

1. Seth, P. P., Siwkowski, A., Allerson, C. R., Vasquez, G., Lee, S., Prakash, T. P., Wancewicz, E. V., Witchell, D. and Swayze, E. E. (2009) Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem., 52, 10-13.
2. Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P. and Bennett, C. F. (2007) Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res., 35, 687-700.
3. Crooke, R. M., Graham, M. J., Lemonidis, K. M., Whipple, C. P., Koo, S. and Perera, R. J. (2005) An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res., 46, 872-878.
4. Nishina, K., Unno, T., Uno, Y., Kubodera, T., Kanouchi, T., Mizusawa, H. and Yokota, T. (2008) Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther., 16, 734-740.
5. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J. et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAS. Nature, 432, 173-178.
6. Zimmermann, T. S., Lee, A. C., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M. et al. (2006) RNAi-mediated gene silencing in non-human primates. Nature, 441, 111-114.
7. Yu, R. Z., Geary, R. S., Flaim, J. D., Riley, G. C., Tribble, D. L., Vanvliet, A. A. and Wedel, M. K. (2009) Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin. Pharmacokinet., 48, 39-50.
8. Olofsson, S. O., Wiklund, O. and Boren, J. (2007) Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc. Health Risk Manag., 3, 491-502.
9. Hansson, G. K. and Libby, P. (2006) The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol., 6, 508-519.
10. Grünweller, A. and Hartmann, R. K. (2007) Locked nucleic acid oligonucleotides: the next generation of antisense agents? Biodrugs, 21, 235-243.
11. Koch, T. and Ørum, H. (2008) Locked nucleic acid. In Crooke, S. T. (ed.), Antisense Drug Technology. CRC Press, Boca Raton, pp. 519-564.
12. Frieden, M., Christensen, S. M., Mikkelsen, N. D., Rosenbohm, C., Thrue, C. A., Westergaard, M., Hansen, H. F., Orum, H. and Koch, T. (2003) Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res., 31, 6365-6372.
13. Zon, G. and Stec, W. (1991) Phosphorothioate oligonucleotides. In Eckstein, F. (ed.), Oligonucleotide Analogues, Chapter 4. Oxford University Press, pp. 102-103.
14. Ullberg, S. (1977) The technique of whole body autoradiography. Cryosectioning of large specimens. Science tools, LKB Inst. J., Special Issue on Whole-body Autoradiography, 2-28.
15. Ullberg, S., Larsson, B. and Tjälve, H. (1982) Autoradiography. In Glenn, J. (ed.), Biological Application of Radiotracers. CRC Press, Boca Raton, FL, CRC Press, pp. 55-108.
16. Moewis, G. (1978) Histopatologisk Teknik. Almqvist & Wiksell Förlag, Stockholm.
17. Fluiter, K., Frieden, M., Vreijling, J., Rosenbohm, C., De Wissel, M. B., Christensen, S. M., Koch, T., Orum, H. and Baas, F. (2005) On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Chembiochem., 6, 1104-1109.
18. Leblanc, M., Belanger, M. C., Julien, P., Tchernof, A., Labrie, C., Belanger, A. and Labrie, F. (2004) Plasma lipoprotein profile in the male cynomolgus monkey under normal, hypogonadal, and combined androgen blockade conditions. J. Clin. Endocrinol. Metab., 89, 1849-1857.
19. Greeve, J., Altkemper, I., Dieterich, J. H., Greten, H. and Windler, E. (1993) Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apob-containing plasma lipoproteins. J. Lipid Res., 34, 1367-1383.
20. Koch, T., Rosenbohm, C., Frydenlund, H. F., Hansen, B., Straarup, E. M. and Kauppinen, S. (2008) Locked nucleic acid: properties and therapeutic aspects. In KURRECK, J. (ed.), Therapeutic Oligonucleotides. The Royal Society of Chemistry, Cambridge, pp. 103-141.
21. Braasch, D. A., Liu, Y. and Corey, D. R. (2002) Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res., 30, 5160-5167.
22. Elayadi, A. N., Braasch, D. A. and Corey, D. R. (2002) Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry, 41, 9973-9981.
23. Elmen, J., Zhang, H. Y., Zuber, B., Ljungberg, K., Wahren, B., Wahlestedt, C. and Liang, Z. (2004) Locked nucleic acid containing antisense oligonucleotides enhance inhibition of HIV-1 genome dimerization and inhibit virus replication. Febs Lett., 578, 285-290.
24. Frieden, M., Christensen, S. M., Mikkelsen, N. D., Rosenbohm, C., Thrue, C. A., Westergaard, M., Hansen, H. F., Orum, H. and Koch, T. (2003) Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res., 31, 6365-6372.
25. Frieden, M., Hansen, H. F. and Koch, T. (2003) Nuclease stability of LNA oligonucleotides and LNA-DNA chimeras. Nucleosides Nucleotides Nucleic Acids, 22, 1041-1043.
26. Grünweller, A., Wyszko, E., Bieber, B., Jahnel, R., Erdmann, V. A. and Kurreck, J. (2003) Comparison of differnt antisense strategies in mammalian cells using locked nucleic acids, 20-OME RNA, phosphorothioates and small intering RNA. Nucleic Acids Res., 31, 3185-3193.
27. Jepsen, J. S., Pfundheller, H. M. and Lykkesfeldt, A. E. (2004) Downregulation of P21 (WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Oligonucleotides, 14, 147-156.
28. Kurreck, J., Wyszko, E., Gillen, C. and Erdmann, V. A. (2002) Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res., 30, 1911-1918.
29. Lennox, K. A., Sabel, J. L., Johnson, M. J., Moreira, B. G., Fletcher, C. A., Rose, S. D., Behlke, M. A., Laikhter, A. L., Walder, J. A. and Dagle, J. M. (2006) Characterization of modified antisense oligonucleotides in Xenopus laevis embryos. Oligonucleotides, 16, 26-42.
30. Mong, J. A., Devidze, N., Goodwillie, A. and Pfaff, D. W. (2003) Reduction of lipocalin-type prostaglandin D synthase in the preoptic area of female mice mimics estradiol effects on arousal and sex behavior. Proc. Natl Acad. Sci. USA, 100, 15206-15211.
31. Simões-Wüst, A. P., Hopkins-Donaldson, S., Sigrist, B., Belyanskaya, L., Stahel, R. A. and Zangemeister-Wittke, U. (2004) A Functionally improved locked nucleic acid antisense oligonucleotide inhibits BCL-2 and BCL-XL Expression and facilitates tumor cell apoptosis. Oligonucleotides, 14, 1-11.
32. Krzystanek, M., Pedersen, T. X., Bartels, E. D., Kjaehr, J., Straarup, E. M. and Nielsen, L. B. (2010) Expression of apolipoprotein B in the kidney attenuates renal lipid accumulation. J. Biol. Chem., 285, 10583-10590.
33. Watanabe, T. A., Geary, R. S. and Levin, A. A. (2006) Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides, 16, 169-180.
34. Gao, W. Y., Han, F. S., Storm, C., Egan, W. and Cheng, Y. C. (1992) Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNAse H: implications for antisense technology. Mol. Pharmacol., 41, 223-229.
35. Stein, C. A., Hansen, J. B., Lai, J., Wu, S., Voskresenskiy, A., Hog, A., Worm, J., Hedtjarn, M., Souleimanian, N., Miller, P. et al. (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res., 38, e3.
36. Akdim, F., Stroes, E. S. and Kastelein, J. J. (2007) Antisense apolipoprotein B therapy: where do we stand? Curr. Opin. Lipidol., 18, 397-400.
37. Kastelein, J. J., Wedel, M. K., Baker, B. F., Su, J., Bradley, J. D., Yu, R. Z., Chuang, E., Graham, M. J. and Crooke, R. M. (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation, 114, 1729-1735.
38. Yu, R. Z., Lemonidis, K. M., Graham, M. J., Matson, J. E., Crooke, R. M., Tribble, D. L., Wedel, M. K., Levin, A. A. and Geary, R. S. (2009) Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem. Pharmacol., 77, 910-919.
39. Schonfeld, G., Patterson, B. W., Yablonskiy, D. A., Tanoli, T. S., Averna, M., Elias, N., Yue, P. and Ackerman, J. (2003) Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J. Lipid Res., 44, 470-478.